Recent News

• 12.06.2025 - Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
• 11.12.2025 - Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
• 11.04.2025 - Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
• 11.03.2025 - Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - 2025 Wells Fargo Healthcare Conference
• 09.03.2025 - Citi’s 2025 Biopharma Back to School Conference
• 08.25.2025 - Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
• 08.25.2025 - Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Recent Filings

• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - 8-K Current report
• 11.04.2025 - EX-99.1 EX-99.1
• 10.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 144 Report of proposed sale of securities